Latest news
Iconovo develops new formulations to strengthen the product portfolio (only in Swedish)
Breddat erbjudande med egen utveckling.
Iconovo AB (publ) utökar erbjudandet med egenutvecklade läkemedelsformuleringar för bolagets inhalatorer. Ett…
Iconovo at CPhI in Madrid
Iconovo attended CPhI in Madrid last week which marked the start of our new collaboration with Stevanato Group and ICOcap. Truly an exiting moment and…
Press releases
Feb 15, 2024, 20:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Feb 15, 2024, 19:35
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:35
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Feb 15, 2024, 19:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Feb 07, 2024, 14:50
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Feb 07, 2024, 14:50
News
IR
English
Regulatory
MAR
Corporate Action
Other
Feb 06, 2024, 14:45
News
IR
English
Corporate Action
Other
Feb 06, 2024, 14:45
News
IR
Swedish
Corporate Action
Other
Feb 01, 2024, 08:00
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
mfn-cus-disclaimer
Feb 01, 2024, 08:00
News
IR
English
Regulatory
MAR
Corporate Action
Other
mfn-cus-disclaimer
Jan 08, 2024, 09:00
News
IR
English
Corporate Action
Other
Jan 08, 2024, 09:00
News
IR
Swedish
Corporate Action
Other
Nov 30, 2023, 09:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
Nov 30, 2023, 09:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Other
Nov 29, 2023, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 29, 2023, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 16, 2023, 11:15
News
IR
English
Corporate Action
Other
Nov 16, 2023, 11:15
News
IR
Swedish
Corporate Action
Other
Oct 31, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
